David Johnston
Nessuna posizione attualmente
Profilo
Il dottor David Johnston è vicepresidente esecutivo dello sviluppo clinico globale presso PPD, Inc. Il dottor Johnston è stato precedentemente impiegato come vicepresidente senior presso Laboratory Corp. of America Holdings. È stato anche membro del consiglio di amministrazione di Locus Biosciences, Inc. Si è laureato presso la University of North Carolina a Greensboro e ha conseguito il dottorato presso la UNC School of Medicine.
Precedenti posizioni note di David Johnston
Società | Posizione | Fine |
---|---|---|
PPD, INC. | President | 01/10/2023 |
THERMO FISHER SCIENTIFIC | Chief Tech/Sci/R&D Officer | - |
Locus Biosciences, Inc.
Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Director/Board Member | - |
LABORATORY CORPORATION OF AMERICA HOLDINGS | Corporate Officer/Principal | - |
Formazione di David Johnston
The University of North Carolina at Greensboro | Undergraduate Degree |
UNC School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
LABORATORY CORPORATION OF AMERICA HOLDINGS | Health Services |
THERMO FISHER SCIENTIFIC | Health Technology |
Aziende private | 2 |
---|---|
Locus Biosciences, Inc.
Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Technology Services |
PPD, Inc.
PPD, Inc. Miscellaneous Commercial ServicesCommercial Services PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. It operates through the Clinical Development Services and Laboratory Services segments. The Clinical Development Services segment focuses in early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment comprises of bioanalytical, vaccine sciences, GMP, central lab and biomarker testing. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC. | Commercial Services |
- Borsa valori
- Insiders
- David Johnston